Skip to content
Search

Latest Stories

Retrospective price adjustment for Priadel

The PSNC and Department of Health and Social Care (DH) have made a retrospective drug tariff price adjustment request to the NHS Business Service Authority for Priadel tablets.

The DH and Pharmaceutical Services Negotiating Committee have retrospectively determined that prescriptions for Priadel 200mg and 400mg tablets for November 2020 will be reimbursed at the new NHS list prices of £7.50 and £8.50 respectively, the PSNC has said.


The latest request for the drug price adjustment follows a recent announcement from the Competition and Markets Authority that Essential Pharma - the manufacturer of the drug - and the DH have agreed on a revised price for Priadel tablets.

According to the CMA announcement, the new prices were effective from November 5.  As per the usual price change mechanism rules, any generic or branded prescriptions for Priadel 200mg and 400mg tablets submitted for payment in November would be reimbursed at the old prices and the new prices would apply from the December 2020 onwards.

Product price details

Drug (pack size)November 2020 Drug Tariff priceRe-determined price for November 2020December 2020 Drug Tariff price
Priadel 200mg modified-release tablets (100)£2.76£7.50£7.50
Priadel 400mg modified-release tablets (100)£4.02£8.50£8.50

The price change mechanism rules state that any list price changes for proprietary products and Drug Tariff Part VIIIA products where the price is based on a proprietary product take effect for any prescriptions dispensed in the following month.

“With the price increases for Priadel tablets coming into effect early in the month of November, a retrospective drug tariff price adjustment was requested by PSNC to ensure that pharmacy contractors are not faced with dispensing the higher priced stock at a loss against prescriptions for Priadel tablets submitted for payment in November 2020,” the pharmacy negotiator said.

“If you have problems obtaining a Part VIII product or problems obtaining the product at the stated Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC website.”

The PSNC has asked pharmacy contractors to include full details of the supplier and price paid for any products sourced above the drug tariff price. It further added that it will investigate the extent of the problem and, where appropriate, discuss the issue with the DH.

Last month, the DH and Priadel manufacturer, Essential Pharma agreed for a price cut to ensure that the drug reaches all the needy hands.

As agreed with the DH, the pharmaceutical company also offered commitments to continue the supply of lithium medication used for the treatment of bipolar disease.

The company’s agreement with the DH follows a probe launched by the CMA over the suspicion that the company may have misused its dominant position in the market to stop the supply of the drug.

Following the launch of the probe by the market regulator, Essential Pharma halted the withdrawal of Priadel and entered into price negotiations with the DH.

The patients might have forced to take more expensive alternative treatments such as Camcolit, if Essential Pharma had opted to withdraw Priadel from the market.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less